注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Bioxel Therapeutics Inc是一家商業化階段的生物製藥公司,利用人工智能方法開發神經科學和免疫腫瘤學領域的轉化藥物。該公司的商業產品IGALMI(開發為BXCL501)是右旋美托咪定的專有舌下薄膜製劑,用於急性治療成人精神分裂症或雙相I或II障礙相關的躁動。BXCL501還被開髮用於急性治療阿爾茨海默病相關的躁動,並作為重度抑鬱症的輔助治療。通過其子公司OnkosXcel Therapeutics,該公司開發了BXCL502作為癡呆症慢性躁動的潛在療法,BXCL701是一種研究性口服先天性免疫激活劑,用於治療侵襲性前列腺癌和晚期實體瘤,這些腫瘤的治療方案尚不成熟。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Vimal D. Mehta | 60 | 2017 | Founder, CEO, President, & Director |
Peter R. Mueller | 66 | 2017 | Independent Chairman & Lead Director |
Alan Breier | - | 2018 | Member of Clinical Advisory Board |
Maurizio Fava | - | 2019 | Member of Clinical Advisory Board |
Steven M. Paul | 72 | - | Member of Advisory Board |
John H. Krystal | - | 2019 | Member of Clinical Advisory Board |
Stephen R. Marder | - | 2018 | Member of Clinical Advisory Board |
George T. Grossberg | - | 2018 | Member of Clinical Advisory Board |
June Bray | 69 | 2021 | Independent Director |
Thomas P. Laughren | - | 2019 | Member of Clinical Advisory Board |
Michal Votruba | 58 | 2019 | Independent Director |
Sheila K. Gujrathi | 53 | - | Member of Advisory Board |
Sheldon H. Preskorn | - | 2018 | Member of Clinical Advisory Board |
Thomas R. Kosten | - | 2019 | Member of Clinical Advisory Board |
Michael P. Miller | 66 | 2022 | Independent Director |
Sandeep Laumas | 55 | 2017 | Independent Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核